USE OF ARSENIC COMPOUNDS TO TREAT TISSUE OR ORGAN REJECTION Russian patent published in 2018 - IPC A61K33/36 A61P37/06

Abstract RU 2665362 C2

FIELD: medicine.

SUBSTANCE: invention relates to use of compound of arsenic sodium metaarsenite (NaAsO₂) for treatment of transplant rejection.

EFFECT: sodium metaarsenite can disrupt the reaction of host lymphocytes to alloantigen, that is, it is an immunosuppressive agent.

3 cl, 12 dwg, 20 tbl, 8 ex

Title	Year	Author	Number
USE OF ARSENIC COMPOUNDS FOR PAIN MANAGEMENT AND INFLAMMATION TREATMENT	2008	Khvang Majkl Yan Yun-Tszin	RU2630574C2
USE OF ARSENIC COMPOUNDS FOR PAIN MANAGEMENT AND INFLAMMATION TREATMENT	2008	Khvang Majkl Jan Jun-Tszin'	RU2468806C2
METHODS AND COMPOSITIONS FOR TREATING CANCER	2009	Burger Angelika Khendriks Khans Rademaker Bernardus	RU2508116C2
2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE-METHYL, POLYMORPHOUS FORMS AND METHODS FOR USE THEREOF	2014	Shejkkh Akhmad J. Mattei Alessandra Van Syu Ts.	RU2693833C2
PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING CANCER AND ITS METASTASES	2006	Rejdmejker Bernardus	RU2401662C2
PHARMACEUTICAL COMPOSITION INCLUDING A HISTONE DEACETYLASE INHIBITOR AND METHOTREXATE	2019	Choi, Young Il Ha, Nina Bae, Daekwon Suh, Dong Hyeon	RU2772018C1
ANTI-CANCER THERAPY, DIRECTED AGAINST CANCER STEM CELLS AND FORMS OF CANCER, RESISTANT TO TREATMENT BY MEDICATIONS	2010	Burger Angelika	RU2568834C2
PROSTAGLANDIN/CYCLOOXYGENASE PATHWAY MODULATION	2007	Vjul'Fert Ehrnst	RU2448712C2
SODIUM ARSENITE-CONTAINING PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MALIGNANT TUMOR	2002	Li Sang Bong Jang Jong Dzhin	RU2310460C2
APPLICATION OF 5'-METHYLTHIOADENOSINE (MTA) FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR GRAFT REJECTION	2005	Vil'Oslada Dias Pablo Avila Saragosa Matias Moreno Bruna Beatris Korrales Isk'Erdo Fernando Berasajn Lasarte Karmen Ruis Garsia-Trevikhano Ehlena	RU2393866C2

Authors

Khvang Majkl

Yan Yun-Tszin

Dates

2018-08-29—Published

2013-11-21—Filed